Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-15
2005-03-15
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S022000, C546S023000
Reexamination Certificate
active
06867215
ABSTRACT:
The present invention provides for pyridoxine phosphonate analogues such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)alkylphosphonates, and (2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)azaalkylphosphonates) and to pyridoxine malonate analogues, such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridylmethyl)malonates), pharmaceutical compositions, and methods for treatment of cardiovascular and related diseases, and diabetes mellitus and related diseases.
REFERENCES:
patent: 3206463 (1965-09-01), Baetz
patent: 3910921 (1975-10-01), Esanu
patent: 3987177 (1976-10-01), Giudicelli et al.
patent: 4032534 (1977-06-01), Chodkiewicz
patent: 4036844 (1977-07-01), Thorne et al.
patent: 4053607 (1977-10-01), Thorne et al.
patent: 4137316 (1979-01-01), Esanu
patent: 4167562 (1979-09-01), Evers
patent: 4361570 (1982-11-01), Fici
patent: 4369172 (1983-01-01), Schor et al.
patent: 4374841 (1983-02-01), Descamps et al.
patent: 4515771 (1985-05-01), Fine
patent: 4567179 (1986-01-01), Lombardino
patent: 4569938 (1986-02-01), Esanu
patent: 4569939 (1986-02-01), Esanu
patent: 4581363 (1986-04-01), Esanu
patent: 4605741 (1986-08-01), Zagnoli et al.
patent: 4696920 (1987-09-01), Bentzen et al.
patent: 4730042 (1988-03-01), Hege et al.
patent: 4735950 (1988-04-01), Esanu
patent: 4735956 (1988-04-01), Baldwin et al.
patent: 4837239 (1989-06-01), Benjamin et al.
patent: 4843071 (1989-06-01), Hohenwarter
patent: 4962121 (1990-10-01), Hamberger et al.
patent: 5001115 (1991-03-01), Sloan
patent: 5053396 (1991-10-01), Blass
patent: 5118505 (1992-06-01), Költringer
patent: 5130324 (1992-07-01), Ulrich et al.
patent: 5132115 (1992-07-01), Wolter et al.
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5213813 (1993-05-01), Kornecki et al.
patent: 5254557 (1993-10-01), Buckle et al.
patent: 5254572 (1993-10-01), Serfontein
patent: 5272165 (1993-12-01), Ulrich et al.
patent: 5278154 (1994-01-01), Lacoste et al.
patent: 5288716 (1994-02-01), Speck
patent: 5326757 (1994-07-01), Demopoulos
patent: 5328453 (1994-07-01), Sibalis
patent: 5372999 (1994-12-01), Schneider et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5441972 (1995-08-01), Ogata et al.
patent: 5504090 (1996-04-01), Neely
patent: 5563126 (1996-10-01), Allen et al.
patent: 5569459 (1996-10-01), Shlyankevich
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5631271 (1997-05-01), Serfontein
patent: 5633228 (1997-05-01), Lewis et al.
patent: 5648335 (1997-07-01), Lewis et al.
patent: 5728684 (1998-03-01), Cheng et al.
patent: 5733884 (1998-03-01), Barbul et al.
patent: 5733916 (1998-03-01), Neely
patent: 5770215 (1998-06-01), Moshyedi
patent: 5795873 (1998-08-01), Allen
patent: 5804163 (1998-09-01), Gibby et al.
patent: 5804594 (1998-09-01), Murad
patent: 5833998 (1998-11-01), Biedermann et al.
patent: 5834446 (1998-11-01), Dow et al.
patent: 5840685 (1998-11-01), Fujii et al.
patent: 5847008 (1998-12-01), Doebber et al.
patent: 5858017 (1999-01-01), Demopulos et al.
patent: 5859051 (1999-01-01), Adams et al.
patent: 5874420 (1999-02-01), Pelleg
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5888514 (1999-03-01), Weisman
patent: 5944020 (1999-08-01), Markov et al.
patent: 6043259 (2000-03-01), Dhalla et al.
patent: 831350 (1976-01-01), None
patent: 863754 (1978-05-01), None
patent: 561 183 (1975-04-01), None
patent: 1 958 226 (1970-05-01), None
patent: 24 61 742 (1976-07-01), None
patent: 37 05 549 (1988-09-01), None
patent: 43 44 751 (1995-06-01), None
patent: 0 121 036 (1984-10-01), None
patent: 0 144 051 (1985-06-01), None
patent: 0 270 026 (1988-06-01), None
patent: 0 416 248 (1991-03-01), None
patent: 0 891 719 (1999-01-01), None
patent: 846376 (1941-03-01), None
patent: 1323941 (1963-12-01), None
patent: 5552 (1967-12-01), None
patent: 5801 (1968-03-01), None
patent: 6453 (1968-12-01), None
patent: 1579544 (1969-08-01), None
patent: 2 034 539 (1970-12-01), None
patent: 2101010 (1972-03-01), None
patent: 2255883 (1975-07-01), None
patent: 2428640 (1980-01-01), None
patent: 1 013 939 (1965-12-01), None
patent: 1172800 (1969-12-01), None
patent: 1 201 014 (1970-08-01), None
patent: 1 297 080 (1972-11-01), None
patent: 1 360 536 (1974-07-01), None
patent: 1 493 993 (1977-12-01), None
patent: 2 254 556 (1992-10-01), None
patent: 48-21959 (1973-07-01), None
patent: 54-17130 (1979-02-01), None
patent: 10-158244 (1998-06-01), None
patent: 2000-26295 (2000-01-01), None
patent: WO 8300085 (1983-01-01), None
patent: WO 9119500 (1991-12-01), None
patent: WO 9418965 (1994-09-01), None
patent: WO 9828310 (1998-07-01), None
patent: WO 9903365 (1999-01-01), None
patent: WO 9953928 (1999-10-01), None
Arbuzov, S., “Pharmacological Properties of the Products of the Condensation of Phenamine with Some Metabolites”,Farmakol. Toksikol., vol. 31, No. 3, pp. 373-376 (1968) (Abstract only).
Arbuzov, S., “Synthesis and Pharmacological Investigation of Some New Compounds Related Structurally to Some Natural Metabolites”,Conf. Hug. Ther. Invest. Pharmacol., Soc. Pharmacol. Hung., pp. 489-502 (1966) (Abstract only).
Aybak, M. et al., “Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension”,Drug Res., vol. 45, No. 12, pp. 1271-1273 (1995).
“B Vitamins May Cut Heart Disease Risk”,Harvard Health Letter, 1 page (1998).
Baliga, B. et al., “Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folic Acid and Pyridoxine”,Endocrine Practice, vol. 6, No. 6, pp. 435-441 (Nov./Dec. 2000).
Barrett, S., “Homocysteine: A Cardiovascular Risk Factor Worth Considering”, http://www.quackwatch.com/03Health Promotion/homocysteine.html, 2 pages (©1997).
Bennett et al., “Vitamin B6—Phosphonic Acids”,J. of Med. and Pharm. Chem., vol. 1, No. 3, pp. 213-221 (1959).
Bernstein, A., “Vitamin B6in Clinical Neurology”,Annals of New York Academy of Sciences, vol. 585, pp. 250-260 (1990).
Berger, A.R. et al., “Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity”,Neurology, vol. 42, No. 7, pp. 1367-1370 (Jul. 1992).
Bhagavan, H. et al., “Effect of Postweanling Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5′-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats”,Pediat. Res., vol. 10, pp. 730-732 (1976).
Bode, W. et al., “Pyridoxal-5′-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6”,J. Nutr., vol. 121, No. 11, pp. 1738-1745 (Nov. 1991).
Chasan-Taber, L. et al., “A Prospective Study of Folate and Vitamin B6and Risk of Myocardial Infarction in US Physicians”,Journal of the American College of Nutrition, vol. 15, No. 2, pp. 136-143 (Apr. 1996).
Cho, Y. et al., “In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis”,J. Nutr., vol. 120, pp. 258-265 (1990).
“Computer Generated Search Reports”, 70 pages (May 1999).
Ebadi, M. et al., “Convulsant Activity of Pyridoxal Sulphate and Phosphonoethyl Pyridoxal: Antagonism by GABA and its Synthetic Analogues”,Neuropharmacology, vol. 22, No. 7, pp. 865-873 (1983).
Ellis, J. et al., “Prevention of Myocardial Infarction by Vitamin B6”,Res. Commun. Molec. Pathol. Pharmacol., vol. 89, No. 2, pp. 208-220 (Aug. 1995).
Folsom, A. et al., “Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study”,Circulation, vol. 98, pp. 204-210 (Jul. 21, 1998).
Fonda, M., “Interaction of Pyridoxal Analogues with Glutamate Apodecarboxylase and Aspartate Apoaminotransferase”,The Journal of Biological Chemistry, vol. 246, No. 7, pp. 2230-2240 (Apr. 10, 1971).
Harada, K.
Desai Rita
Medicure International Inc.
LandOfFree
Cardioprotective phosphonates and malonates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardioprotective phosphonates and malonates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardioprotective phosphonates and malonates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3404192